Evaluation of New Biomarkers in Stage 3 and 4 Endometriosis

Diagnostic Value of Annexin V, sVCAM-1, sICAM-1, Vascular Endothelial Growth Factor, TNF Alpha and Interleukin-6 in Ovarian and Deep Infiltrating Endometriosis, the Changes of These Markers in the Postoperative Period

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05312528

Enrollment

Registered

2022-04-05

Start date

2018-02-01

Completion date

2019-03-01

Last updated

2022-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Brief summary

The diagnostic value of Annexin V, sVCAM-1, sICAM-1, vascular endothelial growth factor and Proinflammatory cytokines (TNF-a and interleukin-6) in ovarian endometriosis and deep infiltrating endometriosis, their levels in organ-specific involvement, their relationship with symptoms, and the changes of these markers in the postoperative period will be evaluated.

Detailed description

Serum Annexin V, sVCAM-1, sICAM-1, vascular endothelial growth factor and proinflammatory cytokines (TNF-a and interleukin-6) values were studied by taking blood samples from all patients before and three months after the operation.

Interventions

PROCEDUREendometriosis surgery

Laparoscopy was performed in the follicular phase of the woman's menstrual cycle and all recognizable endometriotic lesions were treated by bipolar coagulation, resection of endometriotic nodules and ovarian cystectomy.

PROCEDUREother benign condition surgeries

ovarian cystectomy, bilateral tubal ligation, myomectomy etc.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

1\. Stage III and IV endometriosis patients requiring surgery due to chronic pelvic pain or suspected malignancy

Exclusion criteria

1. Malignant disease 2. Ovarian failure 3. Acute pelvic inflammatory disease 4. Smokers 5. Pregnancy 6. Chronic autoimmune disease

Design outcomes

Primary

Measure	Time frame	Description
Diagnostic value of serum Annexin V in endometriosis	Up to 4 months	To determine whether serum Annexin V levels (ng/mL) can be used as diagnostic markers of endometriosis disease.
Diagnostic value of serum sVCAM-1 in endometriosis	Up to 4 months	To determine whether serum sVCAM-1(ng/mL) levels can be used as diagnostic markers of endometriosis disease.
Diagnostic value of serum sICAM-1 in endometriosis	Up to 4 months	To determine whether serum sICAM-1(ng/mL) levels can be used as diagnostic markers of endometriosis disease.
Diagnostic value of serum Vascular Endothelial Growth Factor in endometriosis	Up to 4 months	To determine whether serum Vascular Endothelial Growth Factor (pg/mL) levels can be used as diagnostic markers of endometriosis disease.
Diagnostic value of serum TNF-alpha in endometriosis	Up to 4 months	To determine whether serum TNF-alpha (pg/mL) levels can be used as diagnostic markers of endometriosis disease.
Diagnostic value of serum Interleukin-6 in endometriosis	Up to 4 months	To determine whether serum Interleukin-6 (pg/mL) levels can be used as diagnostic markers of endometriosis disease.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026